Next Generation HIV Vaccines & Therapies
Scientific Organizers: Michel C. Nussenzweig, Robert F. Siliciano, John R. Mascola and Margaret E. Ackerman
Date: March 27 - 30, 2022
|InPerson Location: Fairmont Banff Springs, Banff, AB, Canada|
|Meeting is available as a Livestream, click register button below for more details|
|Meeting is available to view On Demand, click register button below for more details|
For Updated Health and Safety Guidelines for Keystone Symposia in-person meetings, click here
Despite the many years of research, a successful vaccine or cure for HIV-1 remains among the highest priority areas of unmet need in infectious disease. As such, this Keystone Symposia conference was designed to bring together scientists working in the fields of HIV vaccines and/or the pathway to a cure. The program was designed to highlight recent results in both areas. The conference seeks to foster collaborations that will build upon these new results to help accelerate progress and treatment methods. The sessions in this program were developed to include a focus on novel approaches to vaccine development including vaccine immunology, passive therapies, and genetic vaccination. Additionally, results from ongoing human vaccine clinical trials will also be integrated into the conference. Moreover, sessions focused on a cure for HIV will address the problem of viral latency and how it is controlled and will emphasize cure-related human clinical trials. The conference organizers hope to elicit and identify areas of future investigation, encourage new partnerships, and collectively generate the knowledge required to design better vaccines, treatment methods, and networks that will facilitate transformative approaches to prevention and cure for this disease.
Global Health Travel Award Deadline: March 7 2022 details
Scholarship Deadline: December 2 2021 details
Keystone Symposia is committed to maintaining a positive and respectful environment at its meetings. To this end, please review and comply with our policies
We gratefully acknowledge the generous grant for this conference provided by:National Institute of Allergy and Infectious Diseases (NIAID)
Grant No. 1 R13 AI157805-01
Funding for this conference was made possible [in part] by 1 R13 AI157805 - 01 from the National Institute of Allergy and Infectious Diseases. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.